提供支持According to PEdaily,cn, Anovent Pharmaceuticals has closed a new round of financing, led by Sequoia Capital China. The details of this financing haven’t been disclosed.
Founded in 2017, Anovent Pharmaceuticals is an innovative company which is focusing on the research and development, production, and sales of respiratory medicines. As an international pharmaceutical company in the respiratory area, Anovent is dedicated to providing affordable respiratory medicines for patients worldwide.
Anovent Pharmaceuticals has cooperated with Peking University, Fudan University, Shanghai Institute of Materia Medica, Chinese Academy of Sciences("SIMM"), Shenyang Pharmaceutical University and other research and development platforms for pharmaceutical production, and transformed researches to production.
The research and development team of Anovent Pharmaceuticals and its R&D and production base are taking the lead in the industry. Its products of high-end respiratory medicines and delivery solutions, and soft mist technology have gained a great reputation in China. Its soft mist inhalation has applied for several patents and took the first place in this field.
Anovent Pharmaceuticals is the only enterprise of inhaled soft mist in the National Science and Technology Major Project, to promote the respiratory industry in China to an advanced level. The company has research and development centers in Shanghai, Nanchang, and Ningbo, and has previously received financial support from the provincial government of Nanchang.
About Sequoia Capital China
Sequoia Capital China is a VC firm focused on seed-stage, mid-stage, late-stage, and growth investments in the fin-tech sector.
Formed in September 2005, Sequoia Capital China has an impressive and diverse portfolio comprising about 300 dynamic companies that deliver high returns on investment using differentiated technologies and innovative business models, including Alibaba, VIPshop.com, Sina.com, Didi, JD.com, Ourpalm, Qihoo 360, Jumei, Momo, and so on.
渝公网安备 50011202502165号
